ReviewJournal of ovarian research2025
Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches.
Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Escin ameliorates letrozole-induced polycystic ovarian syndrome by modulating inflammatory, oxidative stress, and steroidogenic pathways in Wistar rats: integration of network pharmacology and molecular docking.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Prevalence and Clinical Features of Polyendocrine Metabolic Ovarian Syndrome in the Gulf Cooperation Council Countries: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Immunological mechanisms of low-grade systemic inflammation and its role in endometrial dysfunction in women with polycystic ovary syndrome.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic Ovarian Syndrome (PCOS) is a prevalent and complex endocrine disorder affecting 8-13% of women of reproductive age worldwide. It manifests as a spectrum of clinical symptoms, including irregular menstrual cycles, acne, hirsutism, hyperandrogenism, infertility, ovarian cysts, obesity, and metabolic dysfunction. Women with PCOS are at a significantly higher risk of developing chronic conditions, such as insulin resistance, gestational diabetes, endometrial cancer, cardiovascular diseases, hypertension, and infertility. The etiology of PCOS is multifactorial, with unhealthy dietary patterns, environmental factors, genetic predispositions, and hormonal imbalances being recognized as critical contributors to its pathogenesis. This review provides a comprehensive examination of the intricate association between PCOS and non-communicable diseases, including dyslipidemia, depression, obesity, cardiovascular disease, insulin resistance, hypertension, nonalcoholic fatty liver disease, and diabetes. It also explored the underlying mechanisms linking these conditions to PCOS, offering a detailed perspective on the systemic impact of the disorder. Furthermore, we discuss recent advancements in PCOS management, highlighting the role of lifestyle modifications in dietary interventions and emerging therapeutic strategies. By integrating these insights, this review aimed to provide a holistic understanding of PCOS and its management to improve clinical outcomes and enhance the quality of life of affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.